Voyager Therapeutics, Inc. Contract with Customer, Asset, after Allowance for Credit Loss, Current
Voyager Therapeutics, Inc. (VYGR) had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $222.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $222.00K.
- 2026-03-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $151.00K.
- 2025-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $151.00K.
- 2025-09-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $851.00K.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $222.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $151.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $151.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $851.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $851.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $487.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $676.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.55M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $2.62M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $3.34M 10-K · filed 2025-03-11 |
| 2023-09-30 | $3.25M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $3.35M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $328.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $257.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $225.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $151.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $206.00K 10-Q · filed 2022-05-04 |
| 2021-12-31 | $732.00K 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.17M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.76M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $4.25M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $8.01M 10-K · filed 2022-03-08 |
| 2020-09-30 | $12.69M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $12.69M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $16.28M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $18.50M 10-K · filed 2021-02-25 |
| 2019-09-30 | $11.73M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $8.24M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |